anti-cancer program (Fusion Pharmaceuticals)

N/A

Report date: 2025/06/11 11:11:54
NME

Base Information

Drug Nameanti-cancer program (Fusion Pharmaceuticals)
Drug Alias Nameradiopharmaceutical therapy(Fusion Pharmaceuticals)
ClassificationSmall moleculesRadiation-emitting products
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFusion Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesFusion Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A